Literature DB >> 15520500

Effects of enoxaparin on histomorphometric parameters of bones in rats.

Joanna Folwarczna1, Waldemar Janiec, Marta Gawor, Maria Pytlik, Ilona Kaczmarczyk-Sedlak, Barbara Nowińska.   

Abstract

Enoxaparin sodium is a low-molecular-weight heparin. It is not clear whether the risk of development of osteoporosis after administration of low-molecular-weight heparins is lower than after administration of standard heparin. The aim of the present study was to investigate the effects of enoxaparin on histomorphometric parameters of bones in female Wistar rats (13-15 weeks old at the beginning of the experiment). Enoxaparin was administered at doses of 1000 anti-Xa IU/kg sc daily or 2000 anti-Xa IU/kg sc daily for 4 weeks. Bone mass, mineral and calcium content (in the tibia, femur and L-4 vertebra), length and diameter in the tibia and femur, and histomorphometric parameters of the tibia (periosteal and endosteal transverse growth, width of periosteal and endosteal osteoid, area of the transverse cross-section of the cortical bone in the diaphysis and area of the transverse cross-section of the marrow cavity) and the femur (width of epiphyseal and metaphyseal trabeculae, width of epiphyseal cartilage) were examined. Enoxaparin, administered at doses of 1000 anti-Xa IU/kg sc daily or 2000 anti-Xa IU/kg sc daily for 28 days, induced osteopenic changes in the rat skeletal system. The changes observed in bone histomorphometric parameters indicate that enoxaparin caused the inhibition of bone formation and intensification of bone resorption.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15520500

Source DB:  PubMed          Journal:  Pol J Pharmacol        ISSN: 1230-6002


  3 in total

Review 1.  Parenteral anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  David A Garcia; Trevor P Baglin; Jeffrey I Weitz; Meyer Michel Samama
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

2.  Postpartum osteoporosis and vertebral fractures in two patients treated with enoxaparin during pregnancy.

Authors:  D Ozdemir; A A Tam; A Dirikoc; R Ersoy; B Cakir
Journal:  Osteoporos Int       Date:  2014-08-20       Impact factor: 4.507

3.  Impaired bone healing by enoxaparin via inhibiting the differentiation of bone marrow mesenchymal stem cells towards osteoblasts.

Authors:  Yan Li; Liang Liu; Shuwei Li; Haiyu Sun; Yonghong Zhang; Zhiqing Duan; Dong Wang
Journal:  J Bone Miner Metab       Date:  2021-09-15       Impact factor: 2.626

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.